Sajitha Lulu S

Dr. Sajitha Lulu S

Biotechnology, Vellore Institute of technology (VIT), Vellore, India
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2015 in Natural Product Research
Verified
Journal Article
Closed access
SSSajitha Lulu S
Sajitha Lulu S
ATA Thabitha
A Thabitha
VSVino Sundararajan
Vino Sundararajan
AMArumugam Mohanapriya
Arumugam Mohanapriya
MRMadhusmita Rout
Madhusmita Rout
Nonstructural proteins of hepatitis C virus had drawn much attention for the scientific fraternity in drug discovery due to its important role in the disease. 3D structure of the protein was predicted using molecular modelling protocol. Docking studies of 10 medicinal plant compounds and three drugs available in the market (control) with NS2 protease were employed by using rigid docking approach of AutoDock 4.2. Among the molecules tested for docking study, naringenin and quercetin revealed minimum binding energy of − 7.97 and − 7.95 kcal/mol with NS2 protease. All the ligands were docked deeply within the binding pocket region of the protein. The docking study results showed that these compounds are potential inhibitors of the target; and also all these docked compounds have good inhibition constant, vdW+Hbond+desolv energy with best RMSD value.

20 February 2024 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
DSDevi Soorya Narayana Sasikumar
Devi Soorya Narayana Sasikumar
PTPremkumar Thiruselvam
Premkumar Thiruselvam
VSVino Sundararajan
Vino Sundararajan
RRRadhika Ravindran
Radhika Ravindran
Shoba GunasekaranShoba Gunasekaran
Shoba Gunasekaran
SSSajitha Lulu S
Sajitha Lulu S

7 June 2023 in Frontiers in Medicine
Verified
Journal Article
Open access
TPT. Premkumar
T. Premkumar
SSSajitha Lulu S
Sajitha Lulu S
Objective: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The clinical and epidemiological analysis reported the association between SARS-CoV-2 and neurological diseases. Among neurological diseases, Alzheimer’s disease (AD) has developed as a crucial comorbidity of SARS-CoV-2. This study aimed to understand the common transcriptional signatures between SARS-CoV-2 and AD.Materials and methods: System biology approaches were used to compare the datasets of AD and COVID-19 to identify the genetic association. For this, we have integrated three human whole transcriptomic datasets for COVID-19 and five microarray datasets for AD. We have identified differentially expressed genes for all the datasets and constructed a protein–protein interaction (PPI) network. Hub genes were identified from the PPI network, and hub genes-associated regulatory molecules (transcription factors and miRNAs) were identified for further validation.Results: A total of 9,500 differentially expressed genes (DEGs) were identified for AD and 7,000 DEGs for COVID-19. Gene ontology analysis resulted in 37 molecular functions, 79 cellular components, and 129 biological processes were found to be commonly enriched in AD and COVID-19. We identified 26 hub genes which includes AKT1, ALB, BDNF, CD4, CDH1, DLG4, EGF, EGFR, FN1, GAPDH, INS, ITGB1, ACTB, SRC, TP53, CDC42, RUNX2, HSPA8, PSMD2, GFAP, VAMP2, MAPK8, CAV1, GNB1, RBX1, and ITGA2B. Specific miRNA targets associated with Alzheimer’s disease and COVID-19 were identified through miRNA target prediction. In addition, we found hub genes-transcription factor and hub genes-drugs interaction. We also performed pathway analysis for the hub genes and found that several cell signaling pathways are enriched, such as PI3K-AKT, Neurotrophin, Rap1, Ras, and JAK–STAT.Conclusion: Our results suggest that the identified hub genes could be diagnostic biomarkers and potential therapeutic drug targets for COVID-19 patients with AD comorbidity.


21 November 2018 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
PUP. Ambili Unni
P. Ambili Unni
AAA. M. Mohamed Thoufic Ali
A. M. Mohamed Thoufic Ali
MRMadhusmita Rout
Madhusmita Rout
ATA. Thabitha
A. Thabitha
VSVino Sundararajan
Vino Sundararajan
SSSajitha Lulu S
Sajitha Lulu S

5 June 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
BKBlessy Kiruba
Blessy Kiruba
PNP. S. Athul Narayan
P. S. Athul Narayan
BRBadhari Raj
Badhari Raj
SRS. Rohieth Raj
S. Rohieth Raj
SMSam George Mathew
Sam George Mathew
VSVino Sundararajan
Vino Sundararajan
Bladder cancer (BC) is one of the most prevalent types of cancer in developed countries. BC is characterized by its highly heterogeneous and dynamic nature, with significantly higher morbidity and mortality rates in men compared to women. Diagnosing BC requires traditional methods, such as cystoscopy, which can be invasive and costly. Recent research has heavily focused on multi-omics analysis, including genomics, epigenomics, transcriptomics, proteomics, and metabolomics, for biomarker identification. However, challenges such as computational complexity and data integration prevent these methods from achieving robust diagnostic capabilities. Hence, machine learning (ML), with its ability to process high-dimensional data and identify complex patterns, offers a promising patient outcome. By exploiting genomics, epigenomics, transcriptomics, proteomics, and metabolomics data, these models facilitate the discovery of reliable biomarkers, which are critical for early detection, prognosis, and risk stratification of the disease. Integrated models combining computational techniques with large multi-omics datasets have gained significant attention, enabling the identification of significant BC biomarkers that include genes coding for diverse cellular functions, differentially expressed genes, proteins, and metabolites. A substantial amount of multi-omics data collected from clinics and laboratories are utilized to train powerful ML models such as Support Vector Machines (SVM), random forests (RF), decision trees (DT), and gradient boosting methods (e.g., XGBoost) to perform complex tasks, including biomarker discovery, classification of subtypes and feature selection. This comprehensive review highlights the essence of integrated multiomics-ML approaches for the improvement of prognosis and diagnosis of BC.